ArticlePloS one2018

Novel high-throughput myofibroblast assays identify agonists with therapeutic potential in pulmonary fibrosis that act via EP2 and EP4 receptors.

Patrick Sieber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.